Disseminated cryptococcosis by biological therapy: We must manage the risk
Criptococosis diseminada por terapia biológica, se debe gestionar el riesgo
![Thumbnail](/themes/unisabana//images/thumbnails/articulos_indexados_item.jpg)
Enlaces del Item
URI: http://hdl.handle.net/10818/59952Visitar enlace: https://www.scopus.com/inward/ ...
ISSN: 1204157
DOI: 10.7705/biomedica.6239
Compartir
Estadísticas
Ver Estadísticas de usoCatalogación bibliográfica
Mostrar el registro completo del ítemFecha
2022Resumen
Introduction: Multiple adverse effects have been described for the biological therapy in autoimmune diseases including many secondary to immunosuppression producing bacterial, fungal, or viral infections. Clinical case: We present the case of a 64-year-old female patient with proven disseminated cryptococcosis secondary to the use of tofacitinib. Other possible causes of immunosuppression such as the human immunodeficiency virus (HIV) were ruled out. The patient had been in treatment for rheumatoid arthritis diagnosed three years before. This drug is a biological agent that inhibits JAK enzymes. Very few cases of pulmonary and meningeal cryptococcosis in this type of patient have been described in the literature. Conclusion: This case report should be useful for other clinicians to bear in mind the possibility of this type of invasive fungal infection associated with biological therapy and to take a risk-management approach. © 2022. All Rights Reserved.
Ubicación
Biomedica 42 (2), pp. 218-223
Colecciones a las que pertenece
- Facultad de Medicina [958]